Antibody concentrations to Aβ1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations

被引：42

作者：

Klaver, Andrea C. ^{[1
]}

Finke, John M. ^{[2
]}

Digambaranath, Jyothi ^{[2
]}

Balasubramaniam, Mamtha ^{[1
]}

Loeffler, David A. ^{[1
]}

机构：

[1] William Beaumont Hosp, Beaumont Res Inst, Div Neurol, Royal Oak, MI 48073 USA

[2] Oakland Univ, Dept Chem, Rochester, MI 48309 USA

来源：

INTERNATIONAL IMMUNOPHARMACOLOGY | 2010年 / 10卷 / 01期

关键词：

Alzheimer's disease; Amyloid beta; Anti-amyloid beta antibodies; ELISA; Intravenous immunoglobulin; Oligomers; AMYLOID-BETA-PEPTIDE; ALZHEIMERS-DISEASE PATIENTS; CENTRAL-NERVOUS-SYSTEM; A-BETA; MOUSE MODEL; IMMUNE-RESPONSE; IMMUNIZATION; AUTOANTIBODIES; AUTOIMMUNE; PLASMA;

D O I：

10.1016/j.intimp.2009.10.005

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cognitive improvement in Alzheimer's disease (AD) patients treated with intravenous immunoglobulin (IvIg) has been attributed to its antibodies to amyloid beta (A beta) We compared the concentrations of specific antibodies to soluble A beta 1-42 conformations, namely A beta 1-42 monomer and A beta 1-42 soluble oligomers, between three IvIg preparations. Gamunex, Gammagard. and Flebogamma. To determine specific antibody Concentrations to these A beta 1-42 conformations. nonspecific binding of the IvIg preparations to the An reverse sequence, A beta 42-1. was subtracted These antibodies were measured in untreated IvIg preparations and also after they were treated to dissociate antibody-antigen complexes. because this procedure has been reported to increase the detectable levels of serum anti-A beta antibodies. Antibody levels to A beta 1-42 monomer were significantly higher in untreated Gamunex than in the other two IvIg preparations, and antibody-antigen dissociation increased the measured anti-A beta monomer concentrations in Gamunex and Gammagard Dissociated Gamunex and Gammagard had higher anti-A beta monomer levels than Flebogamma. Generally similar results were found for antibodies to soluble A beta 1-42 oligomers. with the exception that after antibody-antigen dissociation, only Gammagard had significantly higher antibody levels than Flebogamma. These differences in antibody concentrations to A beta 1-42 conformations (particularly to A beta 1-42 soluble oligomers, thought to be the most neurotoxic conformation of soluble A beta) and the increased availability of these antibodies after antibody-antigen complex dissociation have important implications for IvIg treatment of AD patients (C) 2009 Elsevier B V All rights reserved

引用

页码：115 / 119

页数：5

共 39 条

[1] Passive Immunization of the Aβ42(43) C-Terminal-Specific Antibody BC05 in a Mouse Model of Alzheimer's Disease [J].

Asami-Odaka, Asano ;

Obayashi-Adachi, Yuka ;

Matsumoto, Yoshio ;

Takahashi, Hideki ;

Fukumoto, Hiroaki ;

Horiguchi, Takashi ;

Suzuki, Nobuhiro ;

Shoji, Mikio .

NEURODEGENERATIVE DISEASES, 2005, 2 (01) :36-43

[2] Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].

Bard, F ;

Cannon, C ;

Barbour, R ;

Burke, RL ;

Games, D ;

Grajeda, H ;

Guido, T ;

Hu, K ;

Huang, JP ;

Johnson-Wood, K ;

Khan, K ;

Kholodenko, D ;

Lee, M ;

Lieberburg, I ;

Motter, R ;

Nguyen, M ;

Soriano, F ;

Vasquez, N ;

Weiss, K ;

Welch, B ;

Seubert, P ;

Schenk, D ;

Yednock, T .

NATURE MEDICINE, 2000, 6 (08) :916-919

[3] Immune response to Aβ-peptides in peripheral blood from patients with Alzheimer's disease and control subjects [J].

Baril, L ;

Nicolas, L ;

Croisile, B ;

Crozier, P ;

Hessler, C ;

Sassolas, A ;

McCormick, JB ;

Trannoy, E .

NEUROSCIENCE LETTERS, 2004, 355 (03) :226-230

[4]

BURDICK D, 1992, J BIOL CHEM, V267, P546

[5] Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease [J].

DeMattos, RB ;

Bales, KR ;

Cummins, DJ ;

Dodart, JC ;

Paul, SM ;

Holtzman, DM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8850-8855

[6] Human antibodies against amyloid β peptide:: A potential treatment for Alzheimer's disease [J].

Dodel, R ;

Hampel, H ;

Depboylu, C ;

Lin, SZ ;

Gao, F ;

Shock, S ;

Jäckel, S ;

Wei, W ;

Buerger, K ;

Höft, C ;

Hemmer, B ;

Möller, HJ ;

Farlow, M ;

Oertel, WH ;

Sommer, N ;

Du, YS .

ANNALS OF NEUROLOGY, 2002, 52 (02) :253-256

[7] Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease [J].

Dodel, RC ;

Du, Y ;

Depboylu, C ;

Hampel, H ;

Frölich, L ;

Haag, A ;

Hemmeter, U ;

Paulsen, S ;

Teipel, SJ ;

Brettschneider, S ;

Spottke, A ;

Nölker, C ;

Möller, HJ ;

Wei, X ;

Farlow, M ;

Sommer, N ;

Oertel, WH .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2004, 75 (10) :1472-1474

[8] IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders [J].

Fillit, H. ;

Hess, G. ;

Hill, J. ;

Bonnet, P. ;

Toso, C. .

NEUROLOGY, 2009, 73 (03) :180-185

[9] Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial [J].

Gilman, S ;

Koller, M ;

Black, RS ;

Jenkins, L ;

Griffith, SG ;

Fox, NC ;

Eisner, L ;

Kirby, L ;

Rovira, MB ;

Forette, F ;

Orgogozo, JM .

NEUROLOGY, 2005, 64 (09) :1553-1562

[10] Autoimmune responses to amyloid structures of Aβ(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease [J].

Grudena, MA ;

Davudova, TB ;

Malisauskas, M ;

Zamotin, VV ;

Sewell, RDE ;

Voskresenskaya, NI ;

Kostanyan, IA ;

Shrestnev, VV ;

Morozova-Roche, LA .

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2004, 18 (02) :165-171

← 1 2 3 4 →